Orexigen Therapeutics (OREX) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016
August 4, 2016 4:01 PM EDTSAN DIEGO, Aug. 4, 2016 /PRNewswire/ --Â Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2016.
"Earlier this week we completed our acquisition of U.S. rights to Contrave®, transforming Orexigen into a fully integrated commercial pharmaceutical company focused on our mission to improve the health and lives of patients struggling to lose weight," said Mike Narachi, CEO of Orexigen. "With the completion of this acquisition and the development of our independent commercialization capabilities over the past several months,... More
